» Articles » PMID: 35023712

Gold Nanorods with Spatial Separation of CeO Deposition for Plasmonic-Enhanced Antioxidant Stress and Photothermal Therapy of Alzheimer's Disease

Overview
Date 2022 Jan 13
PMID 35023712
Authors
Affiliations
Soon will be listed here.
Abstract

Activities of catalase (CAT) and superoxide dismutase (SOD) of ceria nanoparticles (CeO NPs) provide the possibility for their application in nervous system oxidative stress diseases including Alzheimer's disease (AD). The addition of hot electrons produced by a plasma photothermal effect can expand the photocatalytic activity of CeO to the near-infrared region (NIR), significantly improving its redox performance. Therefore, we coated both ends of gold nanorods (Au NRs) with CeO NPs, and photocatalysis and photothermal therapy in the NIR are introduced into the treatment of AD. Meanwhile, the spatially separate structure enhances the catalytic performance and photothermal conversion efficiency. In addition, the photothermal effect significantly improves the permeability of the blood-brain barrier (BBB) and overcomes the shortcomings of traditional anti-AD drugs. To further improve the therapeutic efficiency, Aβ-targeted inhibitory peptides were modified on the middle surface of gold nanorods to synthesize KLVFF@Au-CeO (K-CAC) nanocomposites. We have verified their biocompatibility and therapeutic effectiveness at multiple levels and , which have a profound impact on the research and clinical transformation of nanotechnology in AD therapy.

Citing Articles

Nanoscale drug formulations for the treatment of Alzheimer's disease progression.

Liu L, He H, Du B, He Y RSC Adv. 2025; 15(6):4031-4078.

PMID: 39926227 PMC: 11803502. DOI: 10.1039/d4ra08128e.


Nanomedicine in the treatment of Alzheimer's disease: bypassing the blood-brain barrier with cutting-edge nanotechnology.

Dong N, Ali-Khiavi P, Ghavamikia N, Pakmehr S, Sotoudegan F, Hjazi A Neurol Sci. 2024; .

PMID: 39638950 DOI: 10.1007/s10072-024-07871-4.


A biomimetic upconversion nanoreactors for near-infrared driven H release to inhibit tauopathy in Alzheimer's disease therapy.

Zhang Q, Li C, Yin B, Yan J, Gu Y, Huang Y Bioact Mater. 2024; 42:165-177.

PMID: 39280581 PMC: 11402069. DOI: 10.1016/j.bioactmat.2024.08.029.


Photobiomodulation in experimental models of Alzheimer's disease: state-of-the-art and translational perspectives.

Huang Z, Hamblin M, Zhang Q Alzheimers Res Ther. 2024; 16(1):114.

PMID: 38773642 PMC: 11106984. DOI: 10.1186/s13195-024-01484-x.


Reactive oxygen species-scavenging nanomaterials for the prevention and treatment of age-related diseases.

Dai Y, Guo Y, Tang W, Chen D, Xue L, Chen Y J Nanobiotechnology. 2024; 22(1):252.

PMID: 38750509 PMC: 11097501. DOI: 10.1186/s12951-024-02501-9.